Articles tagged with Drug Candidates
The Center for Research Innovation in Biotechnology (CRIB) has developed a comprehensive database of active pharmaceutical ingredients with evidence of clinical testing. The database provides valuable information on drug discovery and development, including pricing, sponsors, and intended clinical applications.
Researchers at UCLA Health identified a candidate small molecule, DDL-357, that increases concentrations of secreted clusterin, reducing toxic protein phospho-tau and improving mitochondrial function. The drug also improved memory in treated mice in maze-based cognitive tests.
A team of researchers has discovered a small molecule that can selectively block cell death, which could lead to new treatments for neurodegenerative conditions. By targeting the killer protein BAX, the molecule can prevent excessive cell death in neurons, potentially slowing or halting disease progression.
Researchers have developed a new compound, SHP1705, that selectively attacks glioblastoma stem cells by hijacked circadian clock proteins. The compound was found to be safe and well-tolerated in humans during a phase 1 clinical trial.
A new generative AI model, DiffSMol, has been developed to generate realistic 3D structures of small molecules with promising drug properties. The study achieved a 61.4% success rate in creating novel molecules, outperforming prior research attempts.
Researchers at UCSF's AViDD Center have developed a highly bioavailable, covalent molecule that inhibits coronavirus MPro with potent in vivo efficacy. This discovery holds promise for preventing future coronavirus pandemics.
Researchers successfully treated atherosclerosis and fatty liver disease using DT-109 in nonhuman primates, which has potential as a dual therapy for two common conditions. The compound reduced the formation of atherosclerotic plaques and stopped critical processes that lead to vascular calcification.
Insilico Medicine is presenting significant achievements in cancer therapy and immunology, including AI-powered discovery of potential therapies and novel solutions for unmet needs. The company's Pharma.AI platform has received IND clearance for 10 molecules, with promising results in Phase 2a clinical studies.
A new class of agents has been developed to inhibit hospital germs, particularly targeting the toxin α-hemolysin produced by Staphylococcus aureus. The compound H052 showed high effectiveness in cell culture and animal models, increasing survival rates in infected mice.
Researchers have developed a new approach to personalize treatments for young cancer patients by growing tumors in chicken eggs and analyzing proteins. The technique, which combines genomics and proteomics, was successful in identifying a treatment option for a patient with a rare pediatric cancer.
Researchers developed new AI models, InstaNovo and InstaNovo+, to vastly improve accuracy and discovery in protein science. These models excel in tasks such as de novo peptide sequencing, identifying microorganisms, and discovering novel peptides, with implications for personalized medicine, cancer immunology, and beyond.
Scientists have discovered peptides that bind irreversibly to the transcription factor cJun, permanently blocking its action in cancer cells. The study uses a new screening platform technology and has shown promising results for developing new cancer treatments.
Researchers at the University of Virginia Health System have developed a computational tool called LogiRx that can predict how drugs will affect biological processes in the body. The tool has demonstrated its potential by identifying a promising candidate to prevent heart failure, a leading cause of death worldwide.
Researchers have identified distinct protein degradation patterns in key brain regions for individuals who witnessed trauma, differing from those who experienced it firsthand. Sex-specific differences also emerge, with implications for targeted treatments and a better understanding of PTSD development.
A new study by UCLA Health has discovered a drug that fully reproduces the effects of physical stroke rehabilitation in model mice. The drug, DDL-920, excites parvalbumin neurons, leading to significant recovery in movement control after stroke.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
A Phase 1 clinical trial is enrolling up to 55 healthy adults to test the safety and immunogenicity of a candidate Lassa vaccine. The trial aims to prevent Lassa fever, a viral hemorrhagic disease that can cause permanent hearing loss.
A new drug candidate has been developed to target and eliminate senescent cells in the liver, reducing fat buildup and preventing liver damage. The study demonstrates a safer and more effective approach to treating metabolic dysfunction-associated steatotic liver disease (MASLD) and potentially inhibiting liver cancer development.
A groundbreaking study has identified a dual-target approach that significantly prevents the development of resistance in bacteria. This approach combines membrane disruption with an additional critical cellular pathway, offering a potential solution to mitigate the escalating threat of antimicrobial resistance.
Researchers developed a new method to search through billions of molecules to identify potential anti-inflammatory drug candidates. The method uses computer algorithms to explore vast chemical space and has the potential to speed up the costly drug development process.
Researchers developed a next-generation technology, MycoBCP, using artificial intelligence to screen for antimicrobial compound candidates. This method has already vastly accelerated the team's TB research capabilities and helped identify optimal candidate compounds for drug development.
Recent studies have found that new antibiotics are prone to rapid development of resistance, even before they are widely used. This raises concerns about the effectiveness of these treatments in the long run. To address this issue, researchers call for a shift in antibiotic development prioritizing novel modes of action and responsible...
ISM1745, a potentially best-in-class small molecule inhibitor, has been nominated as a preclinical candidate for the treatment of MTAP-deleted cancers. It targets Protein arginine methyltransferase 5 (PRMT5), which is elevated in various cancers and correlates with poor prognostic outcomes.
Scientists at Insilico Medicine developed a novel gut-restricted PHD inhibitor using generative chemistry engine Chemistry42, promising to repair intestinal mucosal barriers and regulate immune responses in IBD. The compound, ISM5411, demonstrated significant anti-colitis activity without systemic side effects.
Insilico Medicine has nominated ISM8969, an orally available NLRP3 inhibitor, as a potential treatment for various inflammatory diseases. The compound has shown promising results in preclinical evaluation studies, including balanced druggability and efficacy against inflammation.
A study from Emory University reveals that 56-62% of individuals treated for Major Depressive Disorder and Treatment-Resistant Depression are eligible for psilocybin-assisted therapy, which could benefit around 5.1-5.6 million people in the US. The treatment has potential to reduce symptoms of depression with a single dose of 25 mg of ...
Adipo Therapeutics' lead product ADPO-002NP shows promising results in increasing energy expenditure and improving insulin resistance by browning white adipose tissue. The company is now raising $8 million to move the treatment to first-in-human Phase I clinical trials.
Researchers have developed a large-scale drug screening technique that tracks drug targets inside cells, allowing for the identification of potential new drugs. The technology screens candidate drugs 100 times faster than standard manual techniques, enabling the discovery of previously unknown drugs.
A research team at SickKids and U of T has developed a robotic system that allows scientists to test numerous potential therapeutics in arrhythmogenic cardiomyopathy, a leading cause of sudden cardiac death among young adults. The technology enables the identification of five potential therapies for the condition.
Researchers aim to develop small molecule drugs to target neuroinflammation in the brain, which contributes to cognitive decline. The goal is to slow or even cure Alzheimer's disease, offering a potential game-changer for the therapeutic landscape.
A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.
A study published in mAbs reveals that up to one-third of antibody-based drugs exhibit nonspecific binding to unintended targets, a serious concern for patient safety. The Membrane Proteome Array technology helped identify this issue, challenging the long-held belief in absolute antibody specificity.
Researchers from Thomas Jefferson University and the University of Maryland Baltimore developed a promising new vaccine candidate that protects against Lassa fever. The study demonstrated the vaccine effectively prevents severe cases of the disease and death in preclinical animal models, paving the way for research in people.
Johannes Wahl receives EUR 1.5 million ERC Starting Grant to streamline synthesis of nitrogen-containing compounds, accelerating identification of promising drug candidates and tailoring their properties. Late-stage nitrogen insertion enables better adjustment of physical and chemical properties.
A new narrow-spectrum antibiotic, FP 100, has been found to effectively eliminate Fusobacterium nucleatum without harming the oral or gut microbiomes. This breakthrough discovery holds significant implications for treating severe gum disease and preventing related systemic conditions such as colon cancer and Alzheimer's disease.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.
Researchers have identified two compounds with strong antivirulence activity from actinobacteria in the Arctic Sea, targeting EPEC bacteria that cause severe diarrhea. The compounds inhibit virulence factor formation and binding to host cells, reducing disease severity and potential for resistance.
Researchers have used cryo-electron microscopy to reveal the structural basis of how cells regulate ferritin, a protein that stores iron. This understanding could lead to the development of drugs that block ferritin's interaction with NCOA4, slowing down aggressive cancer cells.
Researchers developed a novel EIT-EVA PCB sensor for non-invasive assessment of drug inhibition on ion channels. The system enables real-time monitoring of ion flow changes in response to drug exposure, offering a faster and more efficient alternative to traditional methods.
Researchers at Hokkaido University have developed a comprehensive derivative synthesis method to find new antimicrobial drugs. They identified eight analogs possessing strong MraY inhibitory and antibacterial activity, with one showing promising effectiveness in mouse infection models.
Researchers at Tampere University analyzed the molecular activity of over 10,000 genes to investigate the efficacy of ZED1227, a transglutaminase 2 inhibitor. The study found that ZED1227 effectively prevented gluten-induced intestinal mucosal damage and inflammation in celiac patients.
Researchers have identified a potent and unique way to kill drug-resistant bacteria using a repurposed compound called LEI-800. The compound targets the bacterial enzyme DNA gyrase, which is essential for bacterial growth and has not been targeted by existing antibiotics.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
A recent study by Bryan Roth and colleagues validated the accuracy of AlphaFold2 in modeling ligand binding sites, leading to promising results for drug discovery. The researchers found that up to 54% of potential compounds interacted successfully with the target proteins, paving the way for new treatments.
Researchers have successfully adapted a modified drug molecule to selectively bind to a protein in bacteria, rather than human cells, making it more effective against bacterial infections. This breakthrough could provide a new avenue for treating antibiotic-resistant bacterial infections.
Researchers at Karolinska Institutet have discovered a new class of drugs that block mitochondrial function and reverse diet-induced obesity, fatty liver, and diabetes in mice. The treatment increased fat metabolism, leading to drastic weight loss and restored glucose tolerance.
A team of researchers from MSU and Harvard Medical School has created a promising vaccine candidate for antibiotic-resistant bacteria. The vaccine targets Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA), with high levels of immunity observed in animal trials.
A new statistical-modeling workflow can quickly identify molecular structures of products formed by chemical reactions, accelerating drug discovery and synthetic chemistry. The workflow also enables the analysis of unpurified reaction mixtures, reducing time spent on purification and characterization.
Researchers at Butantan Institute used phage display to screen 12,000 proteins from Schistosoma mansoni, identifying key parasite peptides targeted by macaque antibodies. This approach has potential for developing candidate vaccines against the disease.
Researchers from Rutgers University have developed an oral COVID-19 treatment that inhibits disease progression in animals, paving the way for human trials. The treatment, dubbed Jun12682, interferes with viral papain-like protease and shows promise as a potential replacement for Paxlovid.
Researchers discovered compounds with untapped therapeutic potential for treating BPH, melanogenesis, and nerve damage. Metformin restored sex hormone homeostasis, epimedin B stimulated pigmentation function, and hydralazine suppressed ferroptosis to aid in axon regeneration.
Researchers found that chlorogenic acid enhances osteoblast proliferation and differentiation, while inhibiting RANKL-induced osteoclastogenesis. Administration of chlorogenic acid antagonizes ovariectomized-induced bone loss in rats.
Researchers have developed a new, synthetic lung surfactant that mimics the functionality of animal-derived formulations. The surfactant has shown promise in reducing surface tension and may offer a cheaper alternative to Infasurf.
A newly developed compound is showing promise as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms. The compound overcomes the limitations of current treatment praziquantel by being effective against the larval stage and resistant strains.
Scientists have extracted a powerful antibacterial peptide from African catfish skin mucus, which could help combat antibiotic-resistant bacteria. The peptide, called NACAP-II, has been shown to disrupt bacterial cell membranes at very low concentrations.
A study published in Nature Metabolism reveals that the diabetes drug metformin and solid foods increase a hunger-reducing factor called Lac-Phe, while sugary drinks have minimal effect. This discovery could lead to new anti-obesity treatments and help explain why liquid calories drive obesity.
Researchers have identified a potential path to eliminate the viral reservoir that prevents people from being completely cured of HIV. A new drug candidate, called a proteolysis targeting chimeras (PROTAC) molecule, triggers the degradation of the Nef protein, which suppresses HIV replication and restores immune system detection. This ...
A new multitasking substance has been identified to prevent and treat both flu and COVID-19 infections concurrently. The long-acting recombinant cytokine protein rhIL-7-hyFc demonstrated therapeutic and preventive effects against various respiratory diseases, including COVID-19, influenza virus, and respiratory syncytial virus.
Researchers developed a new recombinant flu vaccine called Hexaplex, which provided superior protection against H1N1 and H3N2 viruses in animal models. The vaccine's combination of six proteins from different groups resulted in strong antibody production and T-cell activation, offering broader immunity.
Researchers have developed a new class of antibiotics that can overcome drug-resistant bacteria by targeting the physical and functional integrity of the bacterial cell wall. This could be a game-changer in treating infections, particularly those caused by resistant strains.